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Background: A previous cost-effectiveness analysis showed that bridge to transplant (BTT) with early design left
ventricular assist devices (LVADs) for advanced heart failure was more expensive than medical management
while appearing less beneﬁcial.
Older LVADs were pulsatile, but current second and third generation LVADs are continuous ﬂow pumps. This
study aimed to estimate comparative cost-effectiveness of BTT with durable implantable continuous ﬂow
LVADs compared to medical management in the British NHS.
Methods and results: A semi-Markovmulti-state economicmodel was built using NHS costs data and patient data
in the British NHS Blood and Transplant Database (BTDB). Quality-adjusted life years (QALYs) and incremental
costs per QALY were calculated for patients receiving LVADs compared to those receiving inotrope supported
medical management. LVADs cost £80,569 ($127,887) at 2011 prices and delivered greater beneﬁt than medical
management. The estimated probabilistic incremental cost-effectiveness ratio (ICER) was £53,527 ($84,963)/
QALY (95%CI: £31,802–£94,853; $50,479–$150,560) (over a lifetime horizon). Estimateswere sensitive to choice
of comparator population, relative likelihood of receiving a heart transplant, time to transplant, and LVAD costs.
Reducing the device cost by 15% decreased the ICER to £50,106 ($79,533)/QALY.
Conclusions: Durable implantable continuous ﬂow LVADs deliver greater beneﬁts at higher costs than medical
management in Britain. At the current UK threshold of £20,000 to £30,000/QALY LVADs are not cost effective
but the ICER now begins to approach that of an intervention for end of life care recently recommended by the
British NHS. Cost-effectiveness estimates are hampered by the lack of randomized trials.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Heart transplant is the optimal treatment for patientswith advanced
heart failure, but this option is dependent on the supply of donor hearts.
Individuals awaiting a donor organmay bemanagedwith variousmed-
ical interventions such as intravenous inotropes. An alternative treat-
ment strategy, often termed bridge to transplant (BTT), is to surgically
implant a left ventricular assist device (LVAD). An LVAD is a mechanicalces, Warwick Medical School,
dom. Tel.: +44 24761 50063;
e).
eliability and freedom frombias
land Ltd. Open access under CC BY-NCpump used to support left ventricle function until a donor heart be-
comes available [1]. The British NHS has had a BTT program for more
than a decade but the assessment of the comparative costs and beneﬁts
of these procedures [2,3] is important in the context of an expanding
candidate population, with increases in the numbers of people suffering
heart failure [4], increasing health care costs [5] and a diminishing sup-
ply of donor hearts [6].
The clinical and cost-effectiveness of BTT programs has been evalu-
ated previously [7–11]. However, these analyses were based on pulsa-
tile ﬁrst generation LVADs. Currently nearly all implants used are
secondor third generation durable implantable continuous ﬂowdevices
(HeartWare HLVAD, Thoratec HeartMate II, Jarvik 2000 FlowMaker, and
Micromed HeartAssist) which are widely perceived to have superior
performance compared to earlier devices [12]. In this paper, we investi-
gate the cost-effectiveness of second and third generation ventricular
assist devices (LVADs) as a bridge to transplant (BTT), compared to
medical management with inotrope support in the British NHS bridge
to heart transplant program.-ND license. 
Table 1
Summary of patient baseline characteristics.a
Variable Medical management (n 307)
Number (%)
LVAD (n 235)b
Number (%)
Age Mean 42, SD 14.2
Median 58
Range 16–66
Mean 44, SD 13.4
Median 47
Range 16–66
Gender Male 237/307 (77.2)
Female 70/307 (32.6)
Male 189/235 (80.4)
Female 46/235 (19.6)
Ethnicity White 86.0%
Asian 8.5%
Black 14%
Other 3.4%.
White 91.0%
Asian 4.4%
Black 3.1%
Other 6%.
NYHAc I 1/307 (0.3)
II 1/307 (0.3)
III 43/307 (14.0)
IV 262/307 (85.3)
I 0/31 (0)
II 1/31 (13.2);
III 12/31 (38.7)
IV 18/31 (58.1)
Systolic BP UA Mean 97 SD (14.07)
Median 97
Range 60–130
Hypertension 43/307 (14.0) 23/203 (11.3)
Inotrope use 307/307 (100) 180/235 (76.59)
Previous open heart surgery None 244/305 (80.0)
1 or more 61/305 (20.0)
UA
AICD 57/307 (18.6) 112/235 (47.7)
Diabetes 20/307 (6.5) 35/209 (16.7)
Smokers
(current + ex-smokers)
59/303 (19.5) 77/196 (39.0)
Previous heart transplant 2/307 (2.4) UA
Antiarrhythmics 117/307 (38.1) UA
Beta blocker use UA 106/235 (45.1)
Angiotensin receptor blocker UA 25/235 (10.6)
Pre-IABP 103/307 (33.6) 68/235 (29.0)
Pre-ECMOd 8/307 (2.6) 8/235 (3.4)
Ace inhibitors UA 94/235 (40)
UA = data unavailable.
a Baseline data for all patients for all characteristics was not always complete.
Depending on how data were accrued patients may have discontinued beta blockers
prior to receiving inotropes and some received both treatments.
b Speciﬁed indications are for patients with: Low cardiac output (Cardiac Index,
C.I. b 2.2 l/min/m2) despite an adequate preload (Central Venous Pressure, CVP N
12 mm Hg or Pulmonary Capillary Wedge Pressure, PCWP N 16 mm Hg) and who
require inotropic and/or Intra-Aortic Balloon Pump (IABP) support for— symptomatic hy-
potension (systolic BP b 90 mm Hg) and secondary organ dysfunction (especially renal
and hepatic); better haemodynamic status than mentioned above, but in a rapid rate of
deterioration such that the patient is unlikely to survive until transplantation.
c New York Heart Association functional class.
d Extracorporeal membrane oxygenation.
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We adapted a previous economic model used to assess the British BTT program [13].
We used a semi-Markov multi-state model in which each patient exists in one of three
mutually exclusive states: (1) alive on LVAD or medical management support; (2) alive
after heart transplant; and (3) dead. The monthly transition probabilities between each
state are represented by the quantities p12, p13 and p23. In the model, these transition
probabilities are not ﬁxed butmay depend on time [13]. The NHS perspective was chosen,
an annual discount rate of 3.5% was applied to both costs and health outcomes [14]. All
costs are reported in 2011 British Pound Sterling. The model was run for time horizons
of 3 years, 10 years, and 50 years to capture lifetime costs and consequences of the
whole cohort. Model outputs included mean life years gained (LYG), mean quality-
adjusted life years (QALYs) gained, mean costs, and mean incremental cost-effectiveness
ratios (ICERs as £($)/LYG and £($)/QALY gained). The model was built using MS Excel.
2.1. Patient characteristics and survival estimates
We used the British Blood and Transplant Database (BTDB), overseen by the British
Cardiothoracic Transplant Audit Group, to derive patient characteristics and survival esti-
mates for themodel. The BTDBholds data collected from the six designated British centers
responsible for undertaking LVAD implantation and heart transplant.Most implants (95%)
were undertaken at 3 centers (23%, 25% and 47%, respectively); there was no evidence
from limited data that performance at centers with less experiencewas inferior. The data-
base holds individual patientmedical history and several baseline characteristics for three
patient categories: (1) all advanced heart failure patients on the waiting list for heart
transplant; (2) recipients of LVAD implants as BTT (LVAD patients); and (3) recipients
of heart transplant. Major characteristics are summarized in Table 1. The LVAD group
included all patients listed in the database receiving a second or third generation
FDA-approved LVAD device between May 2002 and December 2011. Patients receiving
a ﬁrst generation LVAD were excluded. The comparator population, the medical manage-
ment group,was formedby selecting those patients on thewaiting listwhowere receiving
inotropes. In sensitivity analyses all medical management patients, not just those receiv-
ing inotropes, constituted the comparator group.
Transition probabilities between health states were modeled using Kaplan–Meier
(K–M) time to event analyses (Fig. 1) with extrapolation beyond the observed data
where necessary. Constant hazards for survival were ﬁtted to the ﬁrst phase of the K–M
plots (to 3 months for LVAD, and post-heart transplant plots, and to 2 weeks for the
medical management plot), and separately to the second phase of improved survival
until 10% of patients were contributing data (at 23 months for LVAD patients) and to
seven years for those post heart transplant (20% contributing data). This second constant
hazard was used for extrapolation beyond the observed data. In the case of survival after
heart transplant, an adjustment was made so that the hazard became that of the age-
and gender-matched British population. For themedical management group, a single con-
stant hazard was ﬁtted to the K–M function until 10% of patients remained at risk.
We applied the same probability of receiving a donor heart to both LVAD and compar-
ator medical management groups; this was estimated from the observed time to transplant
for LVAD patients. Expert clinical opinion indicated that the probability of receiving a donor
heart beyond three and half years of being listed or of receiving an LVADwas extremely low;
we therefore set this probability at zero after 42 months.
2.2. Health outcomes
In accordancewith current British guidelines [14] health outcomes were measured in
quality-adjusted life years (QALYs). We used New York Heart Association (NYHA) infor-
mation for patients in the BTDB to determine EQ-5D utility scores, using the relationship
between EQ-5D and NYHA for heart failure patients as reported by Gohler et al. [15]. For
those who received an LVAD, NYHA class was recorded at initial registration and at
1 month follow-up. For medically managed patients, EQ-5D utility scores were deter-
mined using theNYHAdata recorded at registration. For thosewho received a heart trans-
plant NYHA class recorded at the 3, 12 and 24 months outpatient visits was used. A
weighted EQ-5D utility score was derived for each health state based on proportions of
patients in eachNYHA class. Health-related quality of lifewas assumed to remain constant
duringmedical management, after implantation with a LVAD [16] and after a heart trans-
plant [1].
2.3. Resource use and cost estimates
Monthly costs were included from date of LVAD implantation, from the date of entry
to the transplant waiting list and from receipt of transplant based on a previous analysis
[13]. Costs were inﬂated to current prices by applying the projected Health Services Cost
Index (HSCI) [17]. We obtained costs of second and third generation LVADs from the six
designated British centers. A weighted mean for the cost of a LVAD was calculated based
on the relative use of the different devices. We estimated LVAD implant procedure costs
using detailed information on stafﬁng and timings from one center. Base case model
input values are summarized in Table 1.
2.4. Sensitivity analyses
We undertook both probabilistic and univariate sensitivity analyses. Uncertainty in
the base case input parameters was explored by running 1000 iterations using standarddistributions for each group of parameters [18], shown in Table 2. Univariate sensitivity
analysis was used to explore the impact of increasing and decreasing base case input
parameters by 30%. We also undertook a number of sensitivity analyses to explore the
impact of differing survival estimates for the medical management patients using:
1) The British BTDB data for all medical management patients, not just those on inotropic
support; 2) the Seattle Heart Failure Model (SHFM) [19] to predict survival based on data
reported in two other studies [20,21]; 3) Data reported for two control groups in the
REMATCH trial: thewhole group (who had amedian survival of 150 days (4.93 months);
[22] and 4) the inotrope dependent medical management patients in the REMATCH trial
[23] forwhom amedian survival of 120 dayswas reported.We also investigated changing
the probability of heart transplant (p12): for medical management patients based on dif-
ferent projections of time to transplant (a log normal ﬁt for time to transplant for all listed
patients and an exponential ﬁt for time to transplant for LVAD patients).
3. Results
There were 235 patients registered on the BTDB as having had a
second or third generation LVAD implanted between May 2002 and
December 2011. Amongst these, 125 received HeartWare HLVAD, 82
Thoratec HeartMate II, 23 Jarvik 2000 FlowMaker, and 5 Micromed
HeartAssist devices, respectively. The mean cost of an LVAD device
was estimated to be £80,569 ($127,887). Patients were mostly male
(80.4%, 95% CI: 74.8–85.0), middle aged (mean age 44 years, 95% CI:
42.7–45.3) and white (89.7%, 95% CI: 81.8–90.9). Approximately 60%
Fig. 1. Time to event analyses using the UKNHS BTDB, showing: i) Observed survival (95% CI) to 10% at risk andmodeled survival (solid line) while supportedwith an LVAD (patients were
censored if alive at end of follow up, on removal of a LVAD for myocardial recovery and on receipt of a transplant); ii) observed survival (95% CI) to 10% at risk andmodeled survival (solid line)
while supported with medical management (patients were censored if alive at end of follow up, if removed from the transplant list, and on receipt of a transplant); iii) time to heart transplant
(patients were censored on death, on removal from the transplant list and if at end of follow up they had not received a donor heart); iv) survival after heart transplant (patients were censored if
alive at end of follow up after heart transplant. (Please note different scales for x axes).
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39.1–75.5).
Fig. 1 illustrates observed and modeled survival of medically
managed and LVAD-supported BTDB patients. At 2 months, survival
was apparently similar for patients receiving an LVAD compared to
those receiving medical management with inotropes (LVAD: 89% vs.
medical management: 83%). Survival was modeled on the observed
data up to the time the proportion at risk was reduced to 10%. For the
307 patients on medical management with inotropes the modeled sur-
vival at 12 months was 29%, while that for the 235 patients supported
with an LVAD modeled survival at 12 months was 71%. Time to trans-
plant also varied considerably. While 75% overall of patients on the
transplant list had had a transplant by 24 months, only approximately
40% of LVAD patients had received a transplant by a similar time,
although again there is uncertainty in the data. The delay to transplant
for LVAD patients reﬂects a combination of their need to recover after
device implant, the low availability of organs and the fact that upon re-
covery after implant they are perceived to be at lower risk than urgent
medical management patients. Survival with a transplant was good,
with over 75% survival at 24 months.
Table 2 shows the ﬁndings from the base case deterministic and
probabilistic cost-effectiveness analysis for the 3 year, 10 year and
life-time (50 years) time horizons. In the base case deterministic analy-
sis, the ICERs for the 3 year, 10 year and life-time time horizons were
£122,730 ($194,410)/QALY, £68,088 ($108,076)/QALY and £55,173
($87,576)/QALY respectively. In the probabilistic analysis, the ICERs
for the 3 year, 10 year and life-time time horizons were £120,510
($191,286)/QALY (95% CI: £79,560 to 251,285; $126,286 to $398,865),
£67,119 ($106,538) (95% CI: £38,756 to £116,681; $61,517 to
$185,208) and £53,527 ($84,963)/QALY (95% CI: £31,802 to £94,853;
$50,479 to $150,560) respectively.Fig. 2 illustrates the probabilistic results distributed on the cost effec-
tiveness plane. Each of the 1000 iterations is represented by one data
point. The mean incremental cost effectiveness of the intervention is
indicated by the slope of the line passing through the scatter points.
Fig. 2 also shows the cost-effectiveness acceptability curves (CEAC) for
3 year, 10 year and lifetime horizons in which the probability of cost
effectiveness is plotted against the health service provider's willingness
to pay for increased beneﬁt. According to the current UK threshold of
£20,000 to £30,000/QALY recommended by NICE, LVADs cannot be
considered to be cost effective. At a higher willingness to pay threshold
of £50,000 ($79,365)/QALY, that might be considered appropriate ac-
cording to end of life criteria [24], the probability that LVADs are
cost-effective is 0%, 13.3% and 40.7%, over the 3 year, 10 year and life-
time horizons respectively.
3.1. Sensitivity analyses
Fig. 3 summarizes the inﬂuence on the deterministic ICER of increas-
ing and decreasing important base case inputs by 30%. These estimates
identify LVAD cost, monthly cost for the LVAD patients, and utility on
LVAD support as the most important drivers of the incremental cost-
effectiveness ratio. In the base case we used a utility of 0.74 for the
post-LVAD health state. This is higher than the 0.66 estimated by
Sharples et al. [13] and used in previous analyses [13,25], but the 0.66
value refers to patients receiving older generation pulsatile devices.
When we used 0.66 rather than 0.74 the ICER increased moderately to
£59,041/QALY; when Sharples et al. utilities were adopted for all health
states the ICER became £59,011/QALY. Table 3 shows the ﬁndings of the
sensitivity analysis undertaken to investigate the impact of survival of
medical management patients, based on data in the literature [20,21]
and as reported in theREMATCH trial.While themedian survival ranged
Table 2
Base case model inputs for the base case cost effectiveness analysis.
Health state transition probabilities (p)
Period Monthly transition probability Standard error Beta distribution parameter
α β
LVAD support until death p13 Month 1–3 0.0577197 0.028 3.91 63.93
Month 4+ 0.0179873 N/A N/A N/A
MM support until death p13 Month 1+ 0.073344 0.058 7.38 93.35
Time to HTa p12 Month 1–42 0.012745641 N/A N/A N/A
Month 42+ 0
Support on HT until deatha p23 Month 1–3 0.070366726 0.0163 17.20 227.25
Month 4 to 284 0.002980948 N/A N/A N/A
Month 284+ As British POP N/A N/A N/A
Health state utilities
Health state Period Mean utility SE Beta distribution parameter
α β
MMb (patients on inotropes) All months 0.55 0.023 237.89 194.63
Post-LVAD All months 0.74 0.075 24.57 8.63
Post HT All months 0.83 0.005 4683.69 959.31
Costs—2011 prices
Item Period Mean cost (2011 £($)) SE Gamma distribution
parameter
α β
LVAD device 80,569 (127,887) N/A N/A N/A
LVAD implant procedure 3728 (5917) N/A N/A N/A
Post-LVAD implant supportc Month 1 110,075 (174,722) 2518 2029.08 55.90
Month 2 13,440 (21,333) 1306 105.95 126.84
Month 3 5110 (8111) 764 44.69 114.32
Month 4 3836 (6089) 607 40.0 95.89
Month 5 3248 (5155) 460 49.89 65.09
Month 6 2326 (3692) 356 42.69 54.48
Month 7+ 1893 (3005) 907 4.35 434.97
Support on MM (inotrope)d Month 1 12,216 (19,390) 1156 111.67 109.39
Month 2 6393 (10,147) 604 112.03 57.06
Month 3+ 5965 (9468) 193 951.25 6.27
HT theater cost LVAD 16,663 (26,449) N/A N/A N/A
MM 11,395 (18,087) N/A N/A N/A
HT assessment cost LVAD 0 (0) N/A N/A N/A
MM 1633 (2592) N/A N/A N/A
Post-HT hospital stay and follow-up Month 1 15,577 (24,725) 1117 832.97 38.70
LVADMonth 1 MM 13,211 (20,970) 961 730.39 33.68
LVAD & MM
Month 2 4331 (6875) 802 29.18 148.40
Month 3 2609 (4141) 470 30.77 84.79
Month 4 2828 (4489) 260 117.87 23.99
Month 5 2179 (3459) 432 25.42 85.70
Month 6 1646 (2613) 138 142.69 11.53
Month 7+ 1410 (2238) 177 62.91 22.41
HT = heart transplant; LVAD = Left ventricular assist device; MM = medical management; POP = age and gender matched population.
a Applied for both BTT with LVAD and MM.
b In sensitivity analysis all medical management patients constituted the comparator group; utility for all MM patient was 0.62.
c Includes device and procedure.
d In sensitivity analysis monthly costs for MMwere Month 1—£4517 ($7170), Month 2—£1,672 ($2654), Month 3—£1,758 ($2790), Month 4—£328 ($521), Month 5—£220 ($349),
Month 6— £244 ($387), Month 7— £287 ($456); these were based on the proportion of inotrope and non-inotrope patients amongst all MM patients and the costs for inotrope and
non-inotrope MM support [9].
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base case ﬁndings (Table 4).When the comparator populationwas con-
stituted from the whole BTDB medical management population, LVAD
was found to be more costly and less effective than medical manage-
ment. However, unlike LVAD recipients of whom 77% were receiving
inotropes, only 20% of these patients were receiving inotrope therapy.
Clinical advice indicated that this population is much less ill than
those given an LVAD. Similarly when a high probability of receiving a
heart transplant was applied to both groups, or if those receiving med-
ical management were allocated a high probability but those receiving
LVADs a low probability as in a previous analysis, LVADs are dominated
or the ICER becomes extremely large.4. Discussion
4.1. Summary of ﬁndings
Weused individual patient data from the British BTDB to investigate
the cost effectiveness of second and third generation LVADs in patients
with advanced heart failure listed for heart transplant. The ﬁndings
suggest that in comparison to medical management, with inotropic
support, individuals implanted with a LVAD had higher mean costs
and higher survival beneﬁt, delivering a probabilistic ICER of £53,527
($84,963)/QALY (95% CI: £31,802 to £94,853; $50,479–$150,560) and
a similar deterministic ICER of £55,173 ($87,576)/QALY for a lifetime
Fig. 2. A: Cost effectiveness plane; and B: cost-effectiveness acceptability curves (CEAC) for 3, 10 and lifetime horizons for the comparison of LVADs versus medical management
with inotropes.
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increased signiﬁcantly.
In previous analyses the use of ﬁrst generation LVADswas not found
to be cost-effective in relation to medical management [9–11,13]. The
improving survival experience for individuals implanted with the
newer second and third generation LVADs has reduced their incremen-
tal cost per gain in QALY. In the only other published cost-effectiveness
analysis of later generation LVADs for heart transplant patients
HeartMate II was compared with medical management and generated
an ICER of £219,705 ($348,738)/QALY for the base-case lifetime horizon
[25]. This is likely to be higher than our result because the authors
assumed in their model that all live patients at 6 months received a
donor heart; at this time 82% and 76% of LVAD and MM patients
remained alive generating only 6% more LVAD patients receiving a
door heart than medical management patients. This does not allow
the relative survival advantage from the LVAD to be fully taken into
account in the model. The present model allows patients to receive a
donor heart for up to four years thereby allowing the survival advantage
in the LVADpopulation to be fully realized. Thus, the difference between
MM and LVAD treatments in lifetime accumulated QALYs in our model
was 2.38 (95% CI: 0.78 to 3.59) compared to 0.55 in the other model. In
sensitivity analysis of the other model all live patients at 18 months
(63% MM and 72% LVAD) received a transplant, providing 0.86 moreFig. 3. Tornado plot of univariate sensitivity analyses around base case input values. Note: chan
increase or decrease to both pre-HT and post-HT costs.lifetime QALYs in the LVAD arm compared to the MM arm (56% more
than the base case) and reducing the ICER to £133,660 ($212,158)/
QALY, about half the base case. To have more patients transplanted
at 6 months than 18 months in the model is somewhat anomalous.
That 82% of LVAD patients should receive a donor heart (base case)
is rather unrealistic and does not correlate with the authors' source
data [26] which reported a 56% transplant rate after 18 months.
The sensitivity analysis demonstrates that our estimates of the ICERs
were reasonably robust to a 30% change in the base case input values.
Reduction in the cost of LVADs, and in the subsequent management
costs for individuals implanted with LVADs, together with improve-
ments in the health related-quality of life of individuals implanted with
LVADs all have the potential to make their use more cost-effective. Our
estimates of ongoing monthly costs were based on those of Sharples
et al. [13] whose analysis was undertaken at relatively early stage in de-
velopment of theUKBTT program,with growing experience it is possible
costs will have reduced. Fig. 3 indicates that a very large reduction (30%)
in this parameter reduces the ICER to £25,000/QALY, however such a
substantial reduction in costs in the seven years since 2006 seems un-
likely. Sensitivity analyses further revealed that the cost effectiveness es-
timate was critically dependent on the choice of comparator population
and the probability of receiving a heart transplant. Importantly however,
under the base case scenario, the ICER was relatively insensitive toges to monthly cost of the LVADs andmedical management (MM) groups included a 30%
Table 3
Base case deterministic and probabilistic results.
Deterministic analysis
Mean cost 2011 British £ (US $) Mean years survival Mean QALYs
3 year time horizon
LVAD 176,594 (280,308) 1.95 1.48
MM 79,637 (126,408) 1.13 0.69
Difference 96,958 (153,902) 0.82 0.79
ICERs (£($)/LYG) 117,728 (186,870)
ICERs (£($)/QALY) 122,730 (194,810)
10 year time horizon
LVAD 212,648 (337,537) 3.81 2.95
MM 91,450 (124,159) 1.72 1.17
Difference 121,198 (192,377) 2.09 1.78
ICERs (£($)/LYG) 57,989 (92,046)
ICERs (£($)/QALY) 68,088 (108,076)
Lifetime model
LVAD 239,832 (380,686) 5.40 4.26
MM 104,106 (165,248) 2.47 1.80
Difference 135,726 (215,438) 2.93 2.46
ICERs (£($)/LYG) 46,322 (73,527)
ICERs (£($)/QALY) 55,173 (87,576)
Probabilistic analysis
Mean cost £[$] (95% CI) Mean years survival (95% CI) Mean QALYs (95% CI)
3 year time horizon
LVAD £177,009 (154,922 to 210,495)
$280,967 (245,908 to 334,119)
1.96 (1.60 to 2.22) 1.49 (1.14 to 1.80)
MM £83,010 (49,888 to 124,933)
$131,762 (79,187 to 198,306)
1.18 (0.68 to 1.81) 0.72 (0.42 to 1.12)
Difference £93,998 (45,307 to 139,435)
$149,203 (71,916 to 221,325)
0.78 (0.09 to 1.36) 0.77 (0.26 to 1.21)
ICERs (£/LYG)
($/LYG)
114,631 (78,800 to 374,982)
181,954 (125,079 to 595,210)
ICERs (£/QALY)
($/QALY)
120,510 (79,560 to 251,285)
191,286 (126,286 to 398,865)
10 year time horizon
LVAD £212,000 (175,724 to 264,432)
$336,508 (278,927 to 419,733)
3.83 (3.07 to 4.41) 2.95 (2.26 to 3.55)
MM £99,240 (57,026 to 169,449)
$157,524 (90,517 to 268,967)
1.87 (1.05 to 3.19) 1.27 (0.73 to 2.15)
Difference £112,760 (33,076 to 179,395)
$178,948 (52,502 to 284,754)
1.96 (0.55 to 2.97) 1.68 (0.63 to 2.51)
ICERs (£/LYG)
($/LYG)
57,530 (35,881 to 99,572)
91,317 (56,954 to 158,051)
ICERs (£/QALY)
($/QALY)
67,119 (38,756 to 116,681)
106,538 (61,517 to 185,208)
Lifetime model
LVAD £240,193 (196,411 to 306,883)
$381,259 (311,763 to 487,116)
5.46 (4.29to 6.56) 4.32 (3.31 to 5.31)
MM £112,802 (65,086 to 197,666)
$179,051 (103,311 to 313,756)
2.67 (1.49 to 4.59) 1.94 (1.07 to 3.33)
Difference £127,391 (36,782 to 179,736)
$202,208 (58,384 to 285,295)
2.79 (0.61 to 4.33) 2.38 (0.78 to 3.59)
ICERs (£/LYG)
($/LYG)
45,659 (30,159 to 86,586)
72,475 (47,871 to 137,438)
ICERs (£/QALY)
($/QALY)
53,527 (31,802 to 94,853)
84,963 (50,469 to 150,560)
MM = medical management.
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from 3.9 to 16.5 months.
We found that time to heart transplant exerted a considerable
inﬂuence on the estimate of cost-effectiveness. The BTDB patients listed
for heart transplant exhibited very different times to heart transplant
depending on whether they were medically managed or had received
a LVAD (Fig. 1). For the base case therefore, since these two manage-
ment strategies aremutually exclusive, we assumed that the probability
of receiving a donor heart was independent of whether individuals
were medically managed or had received a LVAD.4.2. Strengths and limitations
This study used recognized economic modeling techniques and a
large and comprehensive database of patients in Britain treated with
both medical management and LVADs. We undertook a wide range of
sensitivity analysis to investigate the robustness of our ﬁndings. For
our base case analysis we selected BTDB patients who were medically
managed and receiving inotrope medication. Our analysis of the BTDB
indicates that 77% of patients who receive a LVAD are medically man-
aged with inotropes prior to implantation and that the Seattle Heart
Table 4
Summary of results of univariate sensitivity analyses using alternative input sources.
Input parameter Horizon (yrs) ICER £/QALY ($/QALY) Difference in QALYs Difference in costs £ ($)
Base case results 3 122,730 (194,810) 0.79 96,958 (153,902)
10 68,088 (108,076) 1.78 121,198 (192,378)
50 55,173 (87,576) 2.46 135,726 (215,438)
1) Survival probability for MM (p13) based on data for all BTDB MM pa-
tients (constant hazard ﬁt to 3 months & then 3 months to 10% at risk,
costs & utility input for mix of inotrope and non-inotrope patients)
3 −7,423,100a (−11,782,698) −0.02 148,462 (235,654)
10 −430,700a (−683,650) −0.37 159,359 (252,951)
50 −207,054a (−328,657) −0.76 157,361 (249,779)
2) a. Survival probability for MM (p13) based on SHFM [19] model making
use of Schaffer et al. 2009 data [20]
3 122,814 (194,943) 0.80 98,251 (155,954)
10 68,268 (10,836) 1.80 122,882 (195,051)
50 55,058 (87,394) 2.50 137,644 (218,483)
2) b. Survival probability for MM (p13) based on SHFM [19] model making
use of Strueber et al. 2011 data [21]
3 129,178 (205,044) 0.50 64,589 (102,522)
10 61,539 (97,681) 1.17 72,001 (114,287)
50 51,731 (82,804) 1.55 80,183 (127,275)
3) Survival probability for MM (p13) based on REMATCH trial optimum
medical management group [22]
3 119,305 (189,373) 1.05 125,270 (198,841)
10 69,413 (110,179) 2.24 155,484 (246,800)
50 55,203 (87,624) 3.17 174,994 (277,768)
4) Survival probability for MM (p13) based on REMATCH trial inotrope
subgroup of optimummedical management group [23]
3 118,968 (188,838) 1.12 133,244 (211,498)
10 69,723 (109,957) 2.36 164,547 (261,186)
50 55,178 (87,584) 3.36 185,398 (294,283)
5) a. For MM patients probability of heart transplant (p12) based on Log
normal ﬁt to time to HT for all patients (MM and LVADs) and for LVAD
patients probability of heart transplant (p12) based on exponential ﬁt to
time to HT for LVAD patients
3 627,644 (996,260) 0.16 £100,423 (159,402)
10 −404,858a (−642,632) −0.24 97,166 (154,232)
50 −54,168a (−85,981) −1.37 74,210 (117,794)
5) b. Probability of heart transplant (p12) based on Log normal ﬁt for all
patients (MM and LVADs) for both MM and LVAD patients (i.e. equal
opportunity of donor heart in both groups based on log normal ﬁt).
3 283,924 (450,673) 0.38 107,891 (171,256)
10 135,726 (215,438) 0.88 119,439 (189,586)
50 96,319 (152,887) 1.34 129,068 (204,870)
MM = medical management.
a LVADs are dominated by medical management, being more expensive while delivering less beneﬁt.
344 A. Clarke et al. / International Journal of Cardiology 171 (2014) 338–345Failure Model [19] scores for LVADs patients taken from the published
literature predicted survival consistent with that observed for the
“inotrope” BTDB patients on medical management.
Estimating survival for the medical management group required
censoring after receipt of a heart transplant. These time-to-event analyses
are probably not free of bias as censored patients are unlikely to be iden-
tical to the starting populations and such censoring may result in overes-
timation of survival. For this reason, in addition to investigating “virtual”
controls based on Seattle Heart Failure Model [19] scores, we also ex-
plored using the medical management group from the REMATCH trial
in a sensitivity analysis [22]. It should be noted that unlike BTDB patients,
participants in REMATCH were deemed too unwell for heart transplant
mainly due to older age or disease severity. However for this control
group, data were mature (54 deaths amongst 61 patients), there was
very little censoring, andmost (72%)were treatedwith inotropes.Median
survival of the REMATCH controls was nearly half that modeled for the
BTDB inotrope control group (4.9 vs. 9.1 months); despite this, the ICER
barely differed from the base case. We consider that this relatively stable
ICER across the range of medical management group survival values is a
result of costs decreasing in line with survival and QALYs. (As survival
decreases, unfortunately fewer medical management patients are alive
to incur the considerable cost of inotrope support and subsequent heart
transplantation).
We derived EQ-5D utility scores using the NYHA data recorded in
the BTDB, as has been done previously in the literature [15]. There is
inherent uncertainty here associated both with designating an NYHA
class to the patient and with the algorithm used to derive utilities.
Also itmay be argued that theNYHA classiﬁcation does not fully capture
individuals' health-related quality of life and that a disease speciﬁc in-
strument such as theMinnesota LivingwithHeart Failure Questionnaire
or the Kansas City Cardiomyopathy Questionnaire should be used, how-
ever data for these was not recorded in the BTDB. Our sensitivity analy-
sis did not reveal a signiﬁcant impact of EQ-5Dutility scores on the ICER.
As in previous economic evaluations our ﬁndings are limited by the lack
of head-to-head randomized controlled trials comparing alternative
treatment strategies, we strongly recommend the undertaking of a pro-
spective randomized trial that would yield real world results. Howeverin the absence of such data it is appropriate to use individual patient
data from a British population to derive transition probabilities and util-
ity data [9,11].
5. Conclusions
We investigated LVADS used as a bridge to transplant (BTT) in pa-
tients in Britain who were eligible for heart transplant. We found
that when compared to medical management LVADs yielded ICERs
of: £120,510/QALY (95% CI: 79,560 to 251,285) ($191,286/QALY
(95% CI: 126,286 to 398,865)) over 3 years; £67,119/QALY (95% CI:
38,756 to 116,681) ($106,538 (95% CI: 61,517 to 185,208)) over
10 years; and £53,527/QALY (95% CI: 31,802 to 94,853) ($84,963
(95% CI: 50,469 to 150,560)), over a lifetime horizon. Reimburse-
ment decisions vary through time and by country according to the
weight given to economic considerations and to the innovativeness
of the technology. The LVAD base case lifetime ICER begins to ap-
proach that for at least one intervention recently recommended in
the UK by NICE as an end of life treatment for advanced prostate can-
cer at a cost per QALY of between £46,000 ($73,016) and £50,000
($79,365) [24]. If the costs of LVADs were reduced by 15% then the
technology might be eligible under this consideration by NICE. This
ﬁnding is complex for the policy arena and will need to be considered
carefully in the light of the burden of disease, available funding, and
future supply of donor hearts.
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